Inactivating PAPSS2 mutations in a patient with premature pubarche.

Dehydroepiandrosterone (DHEA) sulfotransferase, known as SULT2A1, converts the androgen precursor DHEA to its inactive sulfate ester, DHEAS [corrected], thereby preventing the conversion of DHEA to an active androgen. SULT2A1 requires 3'-phosphoadenosine-5'-phosphosulfate (PAPS) for catalytic activity. We have identified compound heterozygous mutations in the gene encoding human PAPS synthase 2 (PAPSS2) in a girl with premature pubarche, hyperandrogenic anovulation, very low DHEAS levels, and increased androgen levels. In vitro coincubation of human SULT2A1 and wild-type or mutant PAPSS2 proteins confirmed the inactivating nature of the mutations. These observations indicate that PAPSS2 deficiency is a monogenic adrenocortical cause of androgen excess.

[1]  B. Zabel,et al.  Expression profile of Papss2 (3′‐phosphoadenosine 5′‐phosphosulfate synthase 2) during cartilage formation and skeletal development in the mouse embryo , 2007, Developmental dynamics : an official publication of the American Association of Anatomists.

[2]  R. Norman,et al.  Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. , 2006, The Journal of clinical endocrinology and metabolism.

[3]  M. McCarthy,et al.  Obesity and polycystic ovary syndrome , 2006, Clinical endocrinology.

[4]  S. Witchel.  Puberty and polycystic ovary syndrome , 2006, Molecular and Cellular Endocrinology.

[5]  M. Goodarzi,et al.  Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. , 2006, Best practice & research. Clinical endocrinology & metabolism.

[6]  David I. Wilson,et al.  In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development. , 2006, The Journal of clinical investigation.

[7]  B. Allolio,et al.  No evidence for hepatic conversion of dehydroepiandrosterone (DHEA) sulfate to DHEA: in vivo and in vitro studies. , 2005, The Journal of clinical endocrinology and metabolism.

[8]  J. L. San Millán,et al.  The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. , 2005, Endocrine reviews.

[9]  A. Scheidig,et al.  The crystal structure of human PAPS synthetase 1 reveals asymmetry in substrate binding. , 2005, Journal of molecular biology.

[10]  D. Ehrmann.  Polycystic ovary syndrome. , 2004, The New England journal of medicine.

[11]  S. Mundlos,et al.  Loss of chondroitin 6-O-sulfotransferase-1 function results in severe human chondrodysplasia with progressive spinal involvement. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. Shackleton,et al.  Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study , 2004, The Lancet.

[13]  R. Auchus,et al.  Adrenarche – physiology, biochemistry and human disease , 2004, Clinical endocrinology.

[14]  P. Claman.  Men at risk: occupation and male infertility. , 2004, Fertility and sterility.

[15]  C. Strott.  Sulfonation and molecular action. , 2002, Endocrine reviews.

[16]  N. Javitt,et al.  Mutational Analysis of Human Hydroxysteroid Sulfotransferase SULT2B1 Isoforms Reveals That Exon 1B of the SULT2B1 Gene Produces Cholesterol Sulfotransferase, whereas Exon 1A Yields Pregnenolone Sulfotransferase* , 2002, The Journal of Biological Chemistry.

[17]  Y. C. Lee,et al.  Characterization and expression of human bifunctional 3'-phosphoadenosine 5'-phosphosulphate synthase isoforms. , 2002, The Biochemical journal.

[18]  R. Weinshilboum,et al.  Human 3'-phosphoadenosine 5'-phosphosulfate synthetase 2 (PAPSS2) pharmacogenetics: gene resequencing, genetic polymorphisms and functional characterization of variant allozymes. , 2002, Pharmacogenetics.

[19]  L. Ibáñez,et al.  Premature adrenarche--normal variant or forerunner of adult disease? , 2000, Endocrine reviews.

[20]  D. Dewailly,et al.  [Polycystic ovary syndrome]. , 2000, Journal de gynecologie, obstetrique et biologie de la reproduction.

[21]  F. Amalric,et al.  Nuclear localization of PAPS synthetase 1: a sulfate activation pathway in the nucleus of eukaryotic cells , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  M. Bidlingmaier,et al.  Dehydroepiandrosterone replacement in women with adrenal insufficiency. , 1999, The New England journal of medicine.

[23]  R. Cantor,et al.  Mutations in orthologous genes in human spondyloepimetaphyseal dysplasia and the brachymorphic mouse , 1998, Nature Genetics.

[24]  D. Rimoin,et al.  Distinct, autosomal recessive form of spondyloepimetaphyseal dysplasia segregating in an inbred Pakistani kindred. , 1998, American journal of medical genetics.

[25]  M. Warman,et al.  A member of a family of sulfate-activating enzymes causes murine brachymorphism. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  B. Allolio,et al.  Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. , 1998, The Journal of clinical endocrinology and metabolism.

[27]  B. Cockburn,et al.  Deletion and Site-directed Mutagenesis of the ATP-binding Motif (P-loop) in the Bifunctional Murine Atp-Sulfurylase/Adenosine 5′-Phosphosulfate Kinase Enzyme* , 1998, The Journal of Biological Chemistry.

[28]  T. Benraad,et al.  Concentrations of total and free dehydroepiandrosterone in plasma and dehydroepiandrosterone in saliva of normal and hirsute women under basal conditions and during administration of dexamethasone/synthetic corticotropin. , 1990, Clinical chemistry.